Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 142

1.

Neoadjuvant endocrine therapy in primary breast cancer.

Huober J, Krainick-Strobel U, Kurek R, Wallwiener D.

Clin Breast Cancer. 2004 Dec;5(5):341-7. Review.

PMID:
15585070
2.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D.

Cancer Cell. 2004 Aug;6(2):117-27.

3.

Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF.

N Engl J Med. 2004 Aug 19;351(8):781-91.

4.

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.

Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR; ASCO Working Group on Chemotherapy Sensitivity and Resistance Assays.

J Clin Oncol. 2004 Sep 1;22(17):3631-8. Epub 2004 Aug 2.

PMID:
15289488
5.

The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.

Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN.

J Clin Oncol. 2004 Jun 15;22(12):2294-302.

PMID:
15197190
6.

The role of ErbB inhibitors in trastuzumab resistance.

Miller KD.

Oncologist. 2004;9 Suppl 3:16-9. Review.

7.
8.

Synergistic interactions between tamoxifen and trastuzumab (Herceptin).

Argiris A, Wang CX, Whalen SG, DiGiovanna MP.

Clin Cancer Res. 2004 Feb 15;10(4):1409-20.

10.

Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer.

Alkarain A, Slingerland J.

Breast Cancer Res. 2004;6(1):13-21. Epub 2003 Oct 21. Review.

11.

Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.

Ellis MJ, Rosen E, Dressman H, Marks J.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):301-7. Review.

PMID:
14623525
12.

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

J Clin Oncol. 2003 Nov 15;21(22):4165-74. Epub 2003 Oct 14.

PMID:
14559892
13.

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.

Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, Mohsin S, Osborne CK, Chamness GC, Allred DC, O'Connell P.

Lancet. 2003 Aug 2;362(9381):362-9.

PMID:
12907009
14.

Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.

Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L.

Cancer. 2003 Jun 15;97(12):2960-71.

15.

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L.

J Clin Oncol. 2003 Mar 15;21(6):976-83.

PMID:
12637460
16.

Cancer statistics, 2003.

Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ.

CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26.

17.

Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.

Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O; Aberdeen Breast Group.

Clin Breast Cancer. 2002 Oct;3 Suppl 2:S69-74.

PMID:
12435290
18.

Cyclin E and survival in patients with breast cancer.

Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS.

N Engl J Med. 2002 Nov 14;347(20):1566-75. Erratum in: N Engl J Med 2003 Jan 9;348(2):186.

19.

Revision of the American Joint Committee on Cancer staging system for breast cancer.

Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL.

J Clin Oncol. 2002 Sep 1;20(17):3628-36.

PMID:
12202663
20.

Neoadjuvant chemotherapy for operable breast cancer.

Green M, Hortobagyi GN.

Oncology (Williston Park). 2002 Jul;16(7):871-84, 889; discussion 889-90, 892-4, 897-8. Review.

PMID:
12164555

Supplemental Content

Support Center